Aspirin benefits people with COX-2 overexpression
This is what I meant by “The key will be to identify what sub-population (which group of people) will benefit from it….” in the previous post on the protective effects of aspirin.
A study published in the New England Journal of Medicine yesterday compared patients with colorectal cancer who took aspirin with those who didn’t. It turns out that there IS a subgroup of people who benefits more: those who over-express (means “to have an excess of”) COX-2.
What’s COX-2? It’s an enzyme (rings a bell?) that promotes growth of blood vessels in tissues. It is possible that this is the mechanism that leads COX-2 to promote the progression of colorectal cancer.
At the moment, this information is not usable yet in clinical medicine, but this is one road that could lead to better understanding of development of cancer and its prevention.

David Aspirin
versus

Goliath COX-2
Image source







